Zacks Research Has Bullish Estimate for RDY Q4 Earnings

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Investment analysts at Zacks Research increased their Q4 2026 EPS estimates for shares of Dr. Reddy’s Laboratories in a research report issued to clients and investors on Monday, March 17th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.20 for the quarter, up from their previous estimate of $0.19. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.80 per share.

RDY has been the subject of several other research reports. StockNews.com downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Trading Up 1.1 %

Shares of RDY stock opened at $13.73 on Thursday. The business has a 50-day moving average of $13.66 and a 200 day moving average of $14.71. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. Dr. Reddy’s Laboratories has a 1-year low of $12.50 and a 1-year high of $16.89. The stock has a market capitalization of $11.46 billion, a PE ratio of 21.86 and a beta of 0.48.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. EverSource Wealth Advisors LLC lifted its holdings in Dr. Reddy’s Laboratories by 423.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company’s stock worth $29,000 after buying an additional 1,507 shares during the period. Glass Jacobson Investment Advisors llc lifted its stake in Dr. Reddy’s Laboratories by 400.0% in the fourth quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company’s stock worth $32,000 after acquiring an additional 1,600 shares during the period. POM Investment Strategies LLC boosted its holdings in Dr. Reddy’s Laboratories by 400.0% in the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock valued at $36,000 after acquiring an additional 1,820 shares in the last quarter. Farther Finance Advisors LLC increased its position in Dr. Reddy’s Laboratories by 461.0% during the 4th quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company’s stock valued at $40,000 after purchasing an additional 2,093 shares during the period. Finally, Allworth Financial LP raised its holdings in Dr. Reddy’s Laboratories by 447.8% in the 4th quarter. Allworth Financial LP now owns 2,728 shares of the company’s stock worth $41,000 after purchasing an additional 2,230 shares in the last quarter. Hedge funds and other institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.